missing translation for 'onlineSavingsMsg'
Learn More

Invitrogen™ Anthrax Protective Antigen Synthetic Peptide

Catalog No. PEP0210
Change view
Click to view available options
Quantity:
50 μg
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
PEP0210 50 μg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
Catalog No. PEP0210 Supplier Invitrogen™ Supplier No. PEP0210
Only null left

Synthetic Peptide

Anthrax Protective Antigen Synthetic Peptide, PEP-0210, from Invitrogen.

Anthrax infection is initiated by the inhalation, ingestion, or cutaneous contact with Bacillus anthracis endospores. B. anthracis produces three polypeptides that comprise the anthrax toxin: protective antigen (PA), lethal factor (LF), and edema factor (EF). PA binds to two related proteins on the cell surface; these are termed tumor epithelial marker 8 (TEM8)/anthrax toxin receptor (ATR) and capillary morphogenesis protein 2 (CMG2), although it is still unclear which is physiologically relevant. Following PA binding to its receptor, PA is cleaved into two fragments by a furin-like protease. The bound fragment binds both LF and EF; the resulting complex is then endocytosed which allows the translocation of LF and EF into the cytoplasm. These toxins are usually sufficient to cause rapid cell death, and often the death of the organism.

Specifications

Species Bacteria
Purification Method purified
Common Name Anthrax Protective Antigen
Concentration 200 μg/mL
Content And Storage -20°C
Description Synthetic Peptide
Format Liquid
Formulation PBS with 0.1% BSA and 0.02% sodium azide; pH 7.2
For Use With (Application) Blocking Assay, Control
Lyophilized No
Preservative 0.02% sodium azide
Product Type Peptide
Quantity 50 μg
Regulatory Status RUO - research use only
Storage Buffer PBS
Show More Show Less